Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study

Johnson & Johnson (JNJ) reported positive Phase 4 STAR trial results for TREMFYA in treating axial psoriatic arthritis. The drug met primary and major secondary endpoints, showing improvements in disease activity, axial symptoms, and MRI-measured inflammation at Week 24. The safety profile was consistent with previous findings. Detailed results will be presented at a future scientific congress.

Johnson & Johnson (JNJ) reported that 50% of patients in a Phase 2 study of CARVYKTI® (ciltacabtagene autoleucel) for early-line relapsed/refractory multiple myeloma achieved five-year treatment-free remission. The study, presented at the International Myeloma Society Annual Meeting, showed a 69.2% five-year overall survival rate and 60.5-month median progression-free survival. The company suggests earlier treatment may increase long-term remission and disease control.

Johnson & Johnson (JNJ) reported that TREMFYA met primary and major secondary endpoints in a 411-person study for axial psoriatic arthritis, showing improvement in spinal pain, stiffness, and MRI-measured inflammation. The Phase 4 STAR study demonstrated significant reductions in symptoms and inflammation compared to placebo. Detailed results are forthcoming.

Johnson & Johnson (JNJ) reported that 50% of patients in a Phase 2 study of CARVYKTI® for multiple myeloma were alive and progression-free five years after a single infusion. The study, presented at the International Myeloma Society Annual Meeting, showed a 69.2% overall survival rate and 60.5-month median progression-free survival. CARVYKTI is approved in 17 markets and has treated over 13,000 patients globally, according to the company.

Johnson & Johnson (JNJ) reported Phase 3 trial results for TECVAYLI plus DARZALEX FASPRO in relapsed/refractory multiple myeloma, showing improved survival outcomes. The data suggest potential long-term survival benefits, with modeling indicating an 86.6% projected cure fraction. Investors will watch for regulatory updates and real-world adoption.

Johnson & Johnson (JNJ) reported that its drug RYBREVANT, combined with chemotherapy, achieved a median overall survival of 34.3 months in a Phase 3 trial for advanced non-small cell lung cancer, compared to 27.9 months with chemotherapy alone. While the protocol-specified final overall-survival analysis did not reach statistical significance, a prespecified analysis accounting for crossover showed a 43% reduction in the risk of death.